U
Ute Berger
Researcher at Heidelberg University
Publications - 54
Citations - 3417
Ute Berger is an academic researcher from Heidelberg University. The author has contributed to research in topics: Imatinib & Chronic myelogenous leukemia. The author has an hindex of 24, co-authored 54 publications receiving 3340 citations. Previous affiliations of Ute Berger include Hammersmith Hospital & University of Southampton.
Papers
More filters
Journal ArticleDOI
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Andreas Hochhaus,Sebastian Kreil,Amie S. Corbin,P La Rosée,P La Rosée,Martin C. Müller,T. Lahaye,Benjamin Hanfstein,Claudia Schoch,Nicholas C.P. Cross,Ute Berger,Harald Gschaidmeier,Brian J. Druker,Ruediger Hehlmann +13 more
TL;DR: Although the heterogeneous development of imatinib resistance is challenging, the fact that BCR-ABL is active in many resistant patients suggests that the chimeric oncoprotein remains a good therapeutic target.
Journal ArticleDOI
Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases
Claudia Schoch,Susanne Schnittger,Sabina Bursch,D. Gerstner,Andreas Hochhaus,Ute Berger,Ruediger Hehlmann,Wolfgang Hiddemann,T Haferlach +8 more
TL;DR: Interestingly, a wide range in the BCR-ABL/ABL ratio was observed especially in patients who showed 100% Ph-positive metaphases in CA, and differences due to measurement of different target structures have to be kept in mind when using these data for definition of remission status.
Journal ArticleDOI
Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR.
Michael Emig,Susanne Saussele,H. Wittor,A. Weisser,Andreas Reiter,A. Willer,Ute Berger,Ruediger Hehlmann,Nicholas C.P. Cross,Andreas Hochhaus +9 more
TL;DR: It is concluded that real-time pcr with hybridization probes is a reliable and sensitive method to monitor cml patients after therapy.
Journal ArticleDOI
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2
Andreas Reiter,Christoph Walz,Ann E. Watmore,Claudia Schoch,Ilona Blau,Brigitte Schlegelberger,Ute Berger,Nick Telford,Shilani Aruliah,John A Yin,Danny Vanstraelen,Helen F Barker,Peter C Taylor,Aisling O'Driscoll,Fabio Benedetti,Cornelia Rudolph,Hans-Jochem Kolb,Andreas Hochhaus,Rüdiger Hehlmann,Andrew Chase,Nicholas C.P. Cross +20 more
TL;DR: It is concluded that human autoantigen pericentriolar material (PCM1)-JAK2 is a novel, recurrent fusion gene in hematologic malignancies and patients with PCM1- JAK2 disease are attractive candidates for targeted signal transduction therapy.
Journal ArticleDOI
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Kirsten Merx,Martin C. Müller,Sebastian Kreil,T. Lahaye,Peter Paschka,Claudia Schoch,A. Weisser,Christian Kuhn,Ute Berger,Harald Gschaidmeier,Ruediger Hehlmann,Andreas Hochhaus +11 more
TL;DR: In this paper, a real-time RT-PCR approach using fluorescent-labeled hybridization probes (LightCycler technology) was used to determine whether BCR-ABL transcript levels can predict chromosomal response.